Nventa announces additional amendments to Equity Incentive Plan for approval at shareholder meeting



    SAN DIEGO, CA, June 14 /CNW/ - San Diego, California USA - Nventa
Biopharmaceuticals Corporation (TSX:NVN) announced today that it has come to
an agreement with Institutional Shareholder Services Canada Corp. (ISS
Canada), an independent provider of proxy voting and corporate governance
services, with regard to amendments to the Company's 2006 Equity Incentive
Plan for consideration at the upcoming shareholder meeting, to be held June
21, 2007 in Vancouver, Canada. ISS Canada is recommending "FOR" votes for
agenda items proposed at Nventa's shareholder meeting relating to election of
directors, appointment of auditors and amendments to the Company's 2006 Equity
Incentive Plan.
    Specifically, Management and Nventa's Board of Directors worked with ISS
Canada to revise the Company's proposed amendments to its Equity Incentive
Plan as previously disclosed in the Company's Management Information Circular
dated May 11, 2007 as follows:

    
    (i)    at subsection 13(a)(ix), require shareholder approval for any
           reduction in the exercise price of an option granted by the
           Company under the Plan;
    (ii)   at subsection 13(a)(ix), require shareholder approval for any
           extension of the term of an option granted under the Plan;
    (iii)  at subsection 6(e), require shareholder approval for any increase
           in the number of shares available for issuance to non-employee
           directors under the Plan to a number greater than 5 percent of the
           number of outstanding common shares.
    

    These changes resulted in a "FOR" recommendation from ISS Canada.
    "We are very pleased that we were able to come to a mutually beneficial
and agreeable position with ISS Canada with regard to initiatives that we are
taking to our shareholders for approval," stated Gregory M. McKee, Nventa's
President and Chief Executive Officer. "This agreement with ISS exemplifies
our efforts to maintain the highest standards of corporate governance," added
Mr. McKee.
    Shareholders may request copies of the amended Equity Incentive Plan,
which includes the foregoing revisions, by contacting the Company at
(858) 202-4900 or ir@nventacorp.com. Copies of the amended Equity Incentive
Plan will also be available at the upcoming shareholder meeting. About Nventa
Biopharmaceuticals Corporation:

    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa
Biopharmaceuticals Corporation, please visit the Company's website located at
www.nventacorp.com.

    %SEDAR: 00023483E




For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,
dslade@nventacorp.com

Organization Profile

NVENTA BIOPHARMACEUTICALS CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890